|
GraphPad Software Inc
kaplan meier survival estimate Kaplan Meier Survival Estimate, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/kaplan meier survival estimate/product/GraphPad Software Inc Average 90 stars, based on 1 article reviews
kaplan meier survival estimate - by Bioz Stars,
2026-04
90/100 stars
|
Buy from Supplier |
|
Firstline Biopharmaceuticals Corporation
kaplan–meier estimates of overall survival Kaplan–Meier Estimates Of Overall Survival, supplied by Firstline Biopharmaceuticals Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/kaplan–meier estimates of overall survival/product/Firstline Biopharmaceuticals Corporation Average 90 stars, based on 1 article reviews
kaplan–meier estimates of overall survival - by Bioz Stars,
2026-04
90/100 stars
|
Buy from Supplier |
|
SAS institute
kaplan-meier estimate of the survival function of the censoring variable Kaplan Meier Estimate Of The Survival Function Of The Censoring Variable, supplied by SAS institute, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/kaplan-meier estimate of the survival function of the censoring variable/product/SAS institute Average 90 stars, based on 1 article reviews
kaplan-meier estimate of the survival function of the censoring variable - by Bioz Stars,
2026-04
90/100 stars
|
Buy from Supplier |
|
PharMetrics Inc
kaplan-meier estimated survival Kaplan Meier Estimated Survival, supplied by PharMetrics Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/kaplan-meier estimated survival/product/PharMetrics Inc Average 90 stars, based on 1 article reviews
kaplan-meier estimated survival - by Bioz Stars,
2026-04
90/100 stars
|
Buy from Supplier |
|
MBL Life science
kaplan-meier estimator of progression-free (pf) survival (pfs) since diagnosis Kaplan Meier Estimator Of Progression Free (Pf) Survival (Pfs) Since Diagnosis, supplied by MBL Life science, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/kaplan-meier estimator of progression-free (pf) survival (pfs) since diagnosis/product/MBL Life science Average 90 stars, based on 1 article reviews
kaplan-meier estimator of progression-free (pf) survival (pfs) since diagnosis - by Bioz Stars,
2026-04
90/100 stars
|
Buy from Supplier |
|
Johns Hopkins HealthCare
kaplan-meier estimates of overall survival of esophageal cancer patients ![]() Kaplan Meier Estimates Of Overall Survival Of Esophageal Cancer Patients, supplied by Johns Hopkins HealthCare, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/kaplan-meier estimates of overall survival of esophageal cancer patients/product/Johns Hopkins HealthCare Average 90 stars, based on 1 article reviews
kaplan-meier estimates of overall survival of esophageal cancer patients - by Bioz Stars,
2026-04
90/100 stars
|
Buy from Supplier |
|
SAS institute
product-limit survival estimate based on the kaplan-meier survival platform ![]() Product Limit Survival Estimate Based On The Kaplan Meier Survival Platform, supplied by SAS institute, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/product-limit survival estimate based on the kaplan-meier survival platform/product/SAS institute Average 90 stars, based on 1 article reviews
product-limit survival estimate based on the kaplan-meier survival platform - by Bioz Stars,
2026-04
90/100 stars
|
Buy from Supplier |
|
Wolters Kluwer Health
kaplan–meier estimates of 1-year patient survival ![]() Kaplan–Meier Estimates Of 1 Year Patient Survival, supplied by Wolters Kluwer Health, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/kaplan–meier estimates of 1-year patient survival/product/Wolters Kluwer Health Average 90 stars, based on 1 article reviews
kaplan–meier estimates of 1-year patient survival - by Bioz Stars,
2026-04
90/100 stars
|
Buy from Supplier |
|
Addinsoft inc
kaplan–meier estimator of the survival function xlstatlife software ![]() Kaplan–Meier Estimator Of The Survival Function Xlstatlife Software, supplied by Addinsoft inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/kaplan–meier estimator of the survival function xlstatlife software/product/Addinsoft inc Average 90 stars, based on 1 article reviews
kaplan–meier estimator of the survival function xlstatlife software - by Bioz Stars,
2026-04
90/100 stars
|
Buy from Supplier |
|
Verlag GmbH
kaplan-meier survival estimates bias version 11.06 ![]() Kaplan Meier Survival Estimates Bias Version 11.06, supplied by Verlag GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/kaplan-meier survival estimates bias version 11.06/product/Verlag GmbH Average 90 stars, based on 1 article reviews
kaplan-meier survival estimates bias version 11.06 - by Bioz Stars,
2026-04
90/100 stars
|
Buy from Supplier |
|
TIBCO
kaplan–meier survival estimator ![]() Kaplan–Meier Survival Estimator, supplied by TIBCO, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/kaplan–meier survival estimator/product/TIBCO Average 90 stars, based on 1 article reviews
kaplan–meier survival estimator - by Bioz Stars,
2026-04
90/100 stars
|
Buy from Supplier |
Image Search Results
Journal: The Journal of thoracic and cardiovascular surgery
Article Title: Recurrence after Neoadjuvant Chemoradiation and Surgery for Esophageal Cancer: Does the Pattern of Recurrence Differ for Complete Responders and Those with Partial or No response?
doi: 10.1016/j.jtcvs.2009.07.069
Figure Lengend Snippet: Kaplan-Meier Estimates of Recurrence-Free Survival of Esophageal Cancer Patients (n=261) at the Johns Hopkins Hospital, according to Pathological Response at Time of Surgical Resection.
Article Snippet: This is probably because if tumors are aggressive enough to be recalcitrant to neoadjuvant chemoradiation, little additional tumor burden is necessary to cause eventual death. fig ft0 fig mode=article f1 fig/graphic|fig/alternatives/graphic mode="anchored" m1 Open in a separate window Figure 2 caption a7 Kaplan-Meier Estimates of Overall Survival of
Techniques:
Journal: The Journal of thoracic and cardiovascular surgery
Article Title: Recurrence after Neoadjuvant Chemoradiation and Surgery for Esophageal Cancer: Does the Pattern of Recurrence Differ for Complete Responders and Those with Partial or No response?
doi: 10.1016/j.jtcvs.2009.07.069
Figure Lengend Snippet: Kaplan-Meier Estimates of Overall Survival of Esophageal Cancer Patients (n=267) at the Johns Hopkins Hospital, according to Pathological Response at Time of Surgical Resection. The Kaplan-Meier estimates for overall survival indicate that as the extent of pathological response to neoadjuvant therapy increases, there is a significant increase in the overall survival of the patient. It is interesting to note, however, that in our observed cohort, the degree of pathological response to neoadjuvant therapy seemed not to affect patients with early mortality (<10 months) but rather those who survived more than one year.
Article Snippet: This is probably because if tumors are aggressive enough to be recalcitrant to neoadjuvant chemoradiation, little additional tumor burden is necessary to cause eventual death. fig ft0 fig mode=article f1 fig/graphic|fig/alternatives/graphic mode="anchored" m1 Open in a separate window Figure 2 caption a7 Kaplan-Meier Estimates of Overall Survival of
Techniques:
Journal: The Journal of thoracic and cardiovascular surgery
Article Title: Recurrence after Neoadjuvant Chemoradiation and Surgery for Esophageal Cancer: Does the Pattern of Recurrence Differ for Complete Responders and Those with Partial or No response?
doi: 10.1016/j.jtcvs.2009.07.069
Figure Lengend Snippet: Kaplan-Meier Estimates of Overall Survival of Esophageal Cancer Patients who had a complete pathological response to neoadjuvant therapy (n=82) at the Johns Hopkins Hospital, according to whether or not there was cancer recurrence following surgical resection.
Article Snippet: This is probably because if tumors are aggressive enough to be recalcitrant to neoadjuvant chemoradiation, little additional tumor burden is necessary to cause eventual death. fig ft0 fig mode=article f1 fig/graphic|fig/alternatives/graphic mode="anchored" m1 Open in a separate window Figure 2 caption a7 Kaplan-Meier Estimates of Overall Survival of
Techniques:
Journal: The Journal of thoracic and cardiovascular surgery
Article Title: Recurrence after Neoadjuvant Chemoradiation and Surgery for Esophageal Cancer: Does the Pattern of Recurrence Differ for Complete Responders and Those with Partial or No response?
doi: 10.1016/j.jtcvs.2009.07.069
Figure Lengend Snippet: Kaplan-Meier Estimates of Overall Survival of Esophageal Cancer Patients who had a partial pathological response to neoadjuvant therapy (n=108) at the Johns Hopkins Hospital, according to whether or not there was cancer recurrence following surgical resection.
Article Snippet: This is probably because if tumors are aggressive enough to be recalcitrant to neoadjuvant chemoradiation, little additional tumor burden is necessary to cause eventual death. fig ft0 fig mode=article f1 fig/graphic|fig/alternatives/graphic mode="anchored" m1 Open in a separate window Figure 2 caption a7 Kaplan-Meier Estimates of Overall Survival of
Techniques:
Journal: The Journal of thoracic and cardiovascular surgery
Article Title: Recurrence after Neoadjuvant Chemoradiation and Surgery for Esophageal Cancer: Does the Pattern of Recurrence Differ for Complete Responders and Those with Partial or No response?
doi: 10.1016/j.jtcvs.2009.07.069
Figure Lengend Snippet: Kaplan-Meier Estimates of Overall Survival of Esophageal Cancer Patients who had no pathological response to neoadjuvant therapy (n=71) at the Johns Hopkins Hospital, according to whether or not there was cancer recurrence following surgical resection.
Article Snippet: This is probably because if tumors are aggressive enough to be recalcitrant to neoadjuvant chemoradiation, little additional tumor burden is necessary to cause eventual death. fig ft0 fig mode=article f1 fig/graphic|fig/alternatives/graphic mode="anchored" m1 Open in a separate window Figure 2 caption a7 Kaplan-Meier Estimates of Overall Survival of
Techniques: